Methotrexate-Associated Nonalcoholic Fatty Liver Disease with Transaminitis in Rheumatoid Arthritis

Background. The aim of this study was to determine the risk factors of MTX-associated nonalcoholic fatty liver disease (NAFLD) with transaminitis in a cohort of rheumatoid arthritis (RA) patients from Singapore. Methods. Patients who developed ultrasound proven NAFLD with transaminitis while on MTX therapy were identified. The demographic and clinical characteristics of the above patients (cases) were compiled and compared with age- and gender-matched controls who were RA patients on long standing MTX therapy without any episode of transaminitis. Results. Among the 978 patients who had received MTX, the prevalence of MTX-associated NAFLD was 4.7% (46 patients). Compared to the controls, the cases had significantly higher mean cumulative dose of MTX (4.03 ± 2.25 g versus 10.04 ± 9.94 g, P ≤ 0.05), weekly dose of MTX (11.3 ± 4.8 mg versus 13.1 ± 4.4 mg weekly, P = 0.033), and fasting blood glucose (P = 0.029). Following multivariate regression analysis, only cumulative dose of MTX remained significant (P = 0.015). Among the cases, the cumulative dose of MTX was found to have a significant positive correlation with the alanine transaminase (ALT) level (P < 0.05, standardised beta coefficient 0.512). Conclusion. The cumulative dose of MTX was the only independent predictor of MTX-associated NAFLD with transaminitis.

[1]  C. Day,et al.  Treatment of Non-Alcoholic Fatty Liver Disease , 2014, Digestive Diseases.

[2]  M. Budoff,et al.  The Prevalence and Clinical Correlates of Nonalcoholic Fatty Liver Disease (NAFLD) in African Americans: The Multiethnic Study of Atherosclerosis (MESA) , 2013, Digestive Diseases and Sciences.

[3]  Fardina Malik,et al.  Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. , 2013, Pharmacogenomics.

[4]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[5]  J. Hardies,et al.  Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.

[6]  N. Oreiro,et al.  The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population , 2012, Scandinavian journal of rheumatology.

[7]  A. Barton,et al.  MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms , 2011, The Pharmacogenomics Journal.

[8]  Z. Ali,et al.  Prevalence of NAFLD in Healthy and Young Male Individuals , 2011, ISRN gastroenterology.

[9]  J. Scoazec,et al.  Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes , 2010, Arthritis research & therapy.

[10]  D. M. van der Heijde,et al.  Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. , 2009, Clinical and experimental rheumatology.

[11]  A. Avogaro,et al.  Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography(). , 2009, Journal of ultrasound.

[12]  A Kavanaugh,et al.  Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide , 2009, Annals of the rheumatic diseases.

[13]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[14]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[15]  S. Taylor-Robinson,et al.  Non-invasive means of measuring hepatic fat content. , 2008, World journal of gastroenterology.

[16]  B Combe,et al.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[17]  H. McLeod,et al.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? , 2003, Annals of the rheumatic diseases.

[18]  Michael Weisman,et al.  Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate , 2002, Annals of Internal Medicine.

[19]  M. Niveiro,et al.  [Acute liver failure in a patient with methotrexate therapy]. , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[20]  A. Taniguchi,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. , 2002, Pharmacogenetics.

[21]  H. Blom,et al.  The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. , 2001, Arthritis and rheumatism.

[22]  J. Bloomer,et al.  Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. , 1998, International surgery.

[23]  H. Blom,et al.  Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. , 1998, Seminars in arthritis and rheumatism.

[24]  Randall G. Lee,et al.  Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[25]  H. Frenzel,et al.  Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. , 1989, The Journal of rheumatology.

[26]  J. Kremer,et al.  Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. , 1986, Arthritis and rheumatism.